These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 36803186)

  • 1. Prophylactic Agents for Preventing Cardiotoxicity Induced Following Anticancer Agents: A Systematic Review and Meta-Analysis of Clinical Trials.
    Keshavarzian E; Sadighpour T; Mortazavizadeh SM; Soltani M; Motevalipoor AF; Khamas SS; Moazen M; Kogani M; Amin Hashemipour SM; Hosseinpour H; Valizadeh R
    Rev Recent Clin Trials; 2023; 18(2):112-122. PubMed ID: 36803186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ACEI/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis.
    Gao Y; Wang R; Jiang J; Hu Y; Li H; Wang Y
    Heart Fail Rev; 2023 Nov; 28(6):1405-1415. PubMed ID: 37414918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis.
    Yun S; Vincelette ND; Abraham I
    Postgrad Med J; 2015 Nov; 91(1081):627-33. PubMed ID: 26399268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart failure from cancer therapy: can we prevent it?
    Totzeck M; Mincu RI; Heusch G; Rassaf T
    ESC Heart Fail; 2019 Aug; 6(4):856-862. PubMed ID: 31297946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis.
    Kalam K; Marwick TH
    Eur J Cancer; 2013 Sep; 49(13):2900-9. PubMed ID: 23706982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of cardio-protective agents in cardio-preservation in breast cancer patients receiving Anthracyclines ± Trastuzumab: a Meta-analysis of clinical studies.
    Elghazawy H; Venkatesulu BP; Verma V; Pushparaji B; Monlezun DJ; Marmagkiolis K; Iliescu CA
    Crit Rev Oncol Hematol; 2020 Sep; 153():103006. PubMed ID: 32777728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardioprotective Effects and Duration of Beta Blocker Therapy in Anthracycline-Treated Patients: A Systematic Review and Meta-analysis.
    Xu L; Long Y; Tang X; Zhang N
    Cardiovasc Toxicol; 2020 Feb; 20(1):11-19. PubMed ID: 31832905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-Blockers for Primary Prevention of Anthracycline-Induced Cardiac Toxicity: An Updated Meta-Analysis of Randomized Clinical Trials.
    Attar A; Behnagh AK; Hosseini M; Amanollahi F; Shafiekhani P; Kabir A
    Cardiovasc Ther; 2022; 2022():8367444. PubMed ID: 36687509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer.
    Lewinter C; Nielsen TH; Edfors LR; Linde C; Bland JM; LeWinter M; Cleland JGF; Køber L; Braunschweig F; Mansson-Broberg A
    Eur Heart J; 2022 Jul; 43(27):2562-2569. PubMed ID: 34951629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer.
    Ghasemi K; Vaseghi G; Mansourian M
    J Oncol Pharm Pract; 2021 Mar; 27(2):414-427. PubMed ID: 33081570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis.
    Abdel-Qadir H; Ong G; Fazelzad R; Amir E; Lee DS; Thavendiranathan P; Tomlinson G
    Ann Oncol; 2017 Mar; 28(3):628-633. PubMed ID: 28028033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and β-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity.
    Blanter JB; Frishman WH
    Cardiol Rev; 2019; 27(5):256-259. PubMed ID: 31008768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of anthracycline and trastuzumab-induced decline in left ventricular ejection fraction with angiotensin-converting enzyme inhibitors or angiotensin receptor blocker: a narrative systematic review of randomised controlled trials.
    Lee S; Alsamarrai A; Xiao A; Wang TKM
    Intern Med J; 2024 Aug; 54(8):1254-1263. PubMed ID: 38874281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling.
    Reichardt P; Tabone MD; Mora J; Morland B; Jones RL
    Future Oncol; 2018 Oct; 14(25):2663-2676. PubMed ID: 29747541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial.
    Gupta V; Kumar Singh S; Agrawal V; Bali Singh T
    Pediatr Blood Cancer; 2018 Nov; 65(11):e27308. PubMed ID: 30009543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective Effects of ACEI/ARB on Left Ventricular Function in Anthracycline-Induced Chronic Cardiotoxicity: A Meta-Analysis of Randomized Controlled Trials.
    Lin H; Liang G; Wu Y; Chen L
    Cardiology; 2021; 146(4):469-480. PubMed ID: 33946067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dexrazoxane: a cardioprotectant for pediatric cancer patients receiving anthracyclines.
    Wu V
    J Pediatr Oncol Nurs; 2015; 32(3):178-84. PubMed ID: 25366577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?
    Yoon GJ; Telli ML; Kao DP; Matsuda KY; Carlson RW; Witteles RM
    J Am Coll Cardiol; 2010 Nov; 56(20):1644-50. PubMed ID: 21050974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiotoxic Effect of Modern Anthracycline Dosing on Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis of Placebo Arms From Randomized Controlled Trials.
    Jeyaprakash P; Sangha S; Ellenberger K; Sivapathan S; Pathan F; Negishi K
    J Am Heart Assoc; 2021 Mar; 10(6):e018802. PubMed ID: 33660514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.